Cefoxitin Sodium for Injection

Cefoxitin Sodium for Injection kills bacteria by inhibiting bacterial cell wall synthesis, and due to its structural characteristics, it has a high resistance to β-lactamase produced by bacteria. Some common clinical Gram-positive, Gram-negative aerobic and anaerobic pathogens are highly sensitive to this product. Cefoxitin Sodium for Injection is resistant to Pseudomonas aeruginosa, most strains of Enterococcus, and Escherichia coli.

The main ingredient of this product is cefoxitin sodium, and its other scientific name is: (6R,7S)-3-carbamoyloxymethyl-7-methoxy-8-oxo-7-[2(2-thienyl)acetylamino]-5-thia-1-azabicyclo-[4.2.0]oct-2-ene-2-carboxylic acid sodium salt.

This product is white or off-white powder with a slight special odor.

Cefuroxime sodium is mainly used in clinical practice for the following infections caused by sensitive bacteria: 1. Respiratory tract infections. 2. Urinary and reproductive system infections. 3. Intra-abdominal infections (including peritonitis and cholangitis). 4. Infections in bones, joints, skin and soft tissues. 5. Sepsis.

Adults: Intramuscular injection: Mild to moderate infection: daily dose 3g, dissolved in 3.5mL of 1% lidocaine solvent for deep intramuscular injection in 3 times. Intravenous injection: Mild to moderate infection: 1-2g each time dissolved in sterile saline or 10-20mL of 5% glucose injection solution and slowly injected intravenously within 4-6 minutes. Intravenous drip: Severe infection: daily dose can be increased to 6-8g, dissolved in sterile saline, 5-10% glucose solution, dextran solution, compound amino acid solution and M/6 sodium lactate solution for intravenous drip in 3-4 times, and the drip should be completed within half an hour. Dosage for renal insufficiency: For patients with renal insufficiency, the dosage regimen is formulated according to their creatinine clearance: 1-2g every 8-12 hours for patients with creatinine clearance of 30-50mL/min; 1-2g every 12-24 hours for patients with creatinine clearance of 10-29mL/min; 0.5-1g every 12-24 hours for patients with creatinine clearance of 5-9mL/min; 0.5-1g every 24-48 hours for patients with creatinine clearance less than 5mL/min. 　　Children: Intravenous administration: Children aged 2-12 years, 100-150mg/kg per day; in critical cases, the daily dose can be increased to 200mg/kg per day, divided into 3-4 intravenous administrations. The preparation method is the same as that for adults.

The adverse reactions of cefoxitin sodium are generally temporary and reversible. The main adverse reactions are: 1. Occasionally, gastrointestinal reactions such as nausea, vomiting, decreased appetite, abdominal pain, diarrhea, and constipation occur. 2. Occasionally, allergic reactions such as rash, urticaria, erythema, and drug fever occur; rare symptoms of anaphylactic shock. 3. A small number of patients may experience abnormal liver and kidney function after taking the drug. 4. Long-term and high-dose use of this product may cause dysbacteriosis and secondary infection. It may also cause vitamin K and vitamin B deficiency. 5. Intramuscular injection sites may cause nodules and pain; excessive or too fast intravenous injections may cause burning sensations and vascular pain, and severe cases may cause thrombophlebitis.

Patients who are allergic to this product and cephalosporin antibiotics are contraindicated.

Precautions for children: The effectiveness and safety of this product for newborns to 3 months old has not been established. For children 3 months old and older, large doses of this product can lead to eosinophilia and elevated SGOT. Precautions for pregnancy and lactation: This product has not been adequately studied for pregnant women, so pregnant women should use this product only when necessary; this product can be secreted into breast milk at low concentrations, so a warning should be given when breastfeeding women use this product. Precautions for the elderly: No significant differences in safety and effectiveness between the elderly and young have been found in clinical studies and clinical reports, but it cannot be ruled out that the elderly have a higher sensitivity.

1. When cefoxitin sodium is used in combination with aminoglycoside antibiotics, it has a synergistic antibacterial effect, but the combination will increase nephrotoxicity. 2. When cefoxitin sodium is used in combination with strong diuretics such as furosemide, it can increase nephrotoxicity. 3. When cefoxitin sodium is used in combination with probenecid, it can delay the excretion of this product, increase the blood concentration of cefoxitin and prolong its half-life. 4. Cefoxitin sodium can affect alcohol metabolism, increase the concentration of acetaldehyde in the blood, and lead to disulfiram-like reactions (facial flushing, headache, dizziness, abdominal pain, stomach pain, nausea, vomiting, shortness of breath, increased heart rate, decreased blood pressure, as well as drowsiness, hallucinations, etc.).

Keep away from light, tightly closed, in a cool and dry place.

Calculated as C16H17N3O7S2 1.0g

24 months.

Yangtze River Pharmaceutical (Group) Co., Ltd.

• Founded in:

  2001-03-27

• Address:

  No. 1, South Yangtze River Road, Taizhou

• Tax NO.:

  913212007286987632

• Registered Funds:

  133 million yuan

• Website:

  Log in to view

• Email:

  Log in to view